Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glucocorticoid alone versus glucocorticoid plus IVIG for severe drug eruption (SJS/TEN)
ChiCTR-TRC-13003550Phase 4Completed
- Sponsor
- Institute of Dermatology, Chinese Academy of Medical Sciences
- Start
- Jan 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) comparing Glucocorticoid Group with Glucocorticoid plus immunoglobulin Group (2 arms). Primary endpoints: Time to start glucocorticoid dose reduction, Total glucocorticoid dose over 28 days and 1 more. Started Jan 2011; status: completed.
02
Drugs
methylprednisoloneimmune globulin
03
Conditions
Stevens-Johnson syndrome (SJS)toxic epidermal necrolysis (TEN)
Beyond the preview
Go deeper on ChiCTR-TRC-13003550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-13003550.